JP2007537294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537294A5 JP2007537294A5 JP2007513411A JP2007513411A JP2007537294A5 JP 2007537294 A5 JP2007537294 A5 JP 2007537294A5 JP 2007513411 A JP2007513411 A JP 2007513411A JP 2007513411 A JP2007513411 A JP 2007513411A JP 2007537294 A5 JP2007537294 A5 JP 2007537294A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- receptor antagonist
- gaba
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 claims 8
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 8
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 7
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 229960001952 metrifonate Drugs 0.000 claims 2
- 229960001697 physostigmine Drugs 0.000 claims 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 2
- 229960004136 rivastigmine Drugs 0.000 claims 2
- 229960001685 tacrine Drugs 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 claims 1
- -1 3-aminopropyl - (n-butyl) Chemical group 0.000 claims 1
- ONNMDRQRSGKZCN-UHFFFAOYSA-N 3-aminopropyl(butyl)phosphinic acid Chemical group CCCCP(O)(=O)CCCN ONNMDRQRSGKZCN-UHFFFAOYSA-N 0.000 claims 1
- 229940124596 AChE inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 claims 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57133004P | 2004-05-14 | 2004-05-14 | |
| PCT/US2005/016805 WO2005112946A1 (en) | 2004-05-14 | 2005-05-13 | Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537294A JP2007537294A (ja) | 2007-12-20 |
| JP2007537294A5 true JP2007537294A5 (https=) | 2008-04-10 |
Family
ID=35428236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513411A Pending JP2007537294A (ja) | 2004-05-14 | 2005-05-13 | Ｇａｂａｂレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20050267076A1 (https=) |
| EP (1) | EP1750724A4 (https=) |
| JP (1) | JP2007537294A (https=) |
| AU (1) | AU2005244867A1 (https=) |
| CA (1) | CA2566204A1 (https=) |
| WO (2) | WO2005112946A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259844A1 (en) * | 2000-09-22 | 2004-12-23 | Nolan Gerard M. | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage |
| AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
| WO2006091836A1 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Formulations of ladostigil tartrate |
| US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
| ES2632638T3 (es) * | 2005-12-09 | 2017-09-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva |
| TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| US20120225848A1 (en) * | 2009-09-21 | 2012-09-06 | Kleschevnikov Alexander M | Antagonists of GABA-B Receptors to Enhance Neuronal Function, Learning and Memory |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| GB8728483D0 (en) * | 1987-12-04 | 1988-01-13 | Ciba Geigy Ag | Chemical compounds |
| US5300679A (en) * | 1987-12-04 | 1994-04-05 | Ciba-Geigy Corporation | Substituted propane-phosphinic acid compounds |
| US5750542A (en) * | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| TW263504B (https=) * | 1991-10-03 | 1995-11-21 | Pfizer | |
| AU662404B2 (en) * | 1992-05-08 | 1995-08-31 | Novartis Ag | Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids |
| AU1153097A (en) * | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
| TW513409B (en) * | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
| US7119189B2 (en) * | 1997-03-19 | 2006-10-10 | Novartis Ag | Metabotropic GABA [B] receptors, receptor-specific ligands and their uses |
| ATE282625T1 (de) * | 1997-06-23 | 2004-12-15 | Polychip Pharmaceuticals Pty | Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens |
| US6245911B1 (en) * | 1997-12-05 | 2001-06-12 | Eisai Co., Ltd. | Donepezil polycrystals and process for producing the same |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9906882D0 (en) * | 1999-03-25 | 1999-05-19 | Novartis Ag | Organic compounds |
| DK1086706T3 (da) * | 1999-03-31 | 2004-03-08 | Eisai Co Ltd | Stabiliserede sammensætninger indeholdende nootropiske lægemidler |
| US20010036949A1 (en) * | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
-
2005
- 2005-05-13 AU AU2005244867A patent/AU2005244867A1/en not_active Abandoned
- 2005-05-13 WO PCT/US2005/016805 patent/WO2005112946A1/en not_active Ceased
- 2005-05-13 CA CA002566204A patent/CA2566204A1/en not_active Abandoned
- 2005-05-13 WO PCT/US2005/016802 patent/WO2005112908A1/en not_active Ceased
- 2005-05-13 US US11/129,026 patent/US20050267076A1/en not_active Abandoned
- 2005-05-13 EP EP05748406A patent/EP1750724A4/en not_active Withdrawn
- 2005-05-13 US US11/129,027 patent/US20050267077A1/en not_active Abandoned
- 2005-05-13 JP JP2007513411A patent/JP2007537294A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535437A5 (https=) | ||
| JP2002532392A5 (https=) | ||
| JP2006500370A5 (https=) | ||
| JP2010503695A5 (https=) | ||
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP2006512417A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| JP2008500390A5 (https=) | ||
| ES2655881T5 (es) | 2,4,6-Trifluoro-N-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-benzamida para el tratamiento de la migraña a través de la vía oral o intravenosa | |
| MA31663B1 (fr) | Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe | |
| JP2010521417A5 (https=) | ||
| CA2789014A1 (en) | Methods and compositions for improving cognitive function | |
| CN101538218B (zh) | 用于治疗或预防退行性和炎症性疾病的药物组合物 | |
| JP2007537294A5 (https=) | ||
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| JP2009508960A5 (https=) | ||
| JP2013518914A5 (https=) | ||
| JP2012502103A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib | |
| MX2010002192A (es) | Compuesto de tetrahidroquinolina que antagonizan el receptor tsh. | |
| EA201001100A1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение | |
| Marcellin et al. | CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS: 476 | |
| JP2006514681A5 (https=) |